BD Receives FDA Approval For The BD FocalPoint(TM) GS Imaging System To Enhance The Detection Of Cervical Cancer

BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), announced today that it received U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) for the BD FocalPoint(TM) GS Imaging System. This innovative new system is designed to enhance cervical cancer screening for cytology laboratories using the BD SurePath(TM) Pap test slides to detect evidence of squamous carcinoma, adenocarcinoma and their usual precursor conditions.

More: continued here

Filed under: Cervical Cancer on December 6th, 2008